Drug Metabolism and Pharmacokinetics Staff
Jose Marengo, Ph.D.
Development Scientist
Education
José obtained his B.S. in Chemistry with a minor in Biology from Pontificia Universidad Católica de Puerto Rico and attended The Ohio State University for graduate courses.
Brief Background
Jose’s professional interests and experience span over 30 years and range from EPA-regulated Pesticide Registration and Evaluation (Battelle Memorial Institute), Drug Discovery, Drug Metabolism, Bioanalysis, first-in-man metabolite ID, reviewer of Influenza Hemagglutination Inhibition assays/validation packages for the development of a cell-derived influenza vaccine (Solvay Pharmaceuticals, Inc./AbbVie), and GLP-regulated Drug Development (AtheroGenics, Inc.). He has extensive experience in the development of LC-MS/MS bioanalytical methods for small molecules and has focused a great part of his career on in vitro metabolic stability testing and on in vitro/in vivo metabolite profiling and identification. He was a key contributor to the data packages for EIDD-2801, which is marketed by Merck as Malnupiravir for the treatment of COVID-19; EIDD-2173, currently in Phase 2 clinical trials with Antios Therapeutics for the treatment of chronic hepatitis B; and EIDD-2023, that was successfully out-licensed to AbbVie as an oral treatment for Hepatitis C. José oversees the chemical and metabolic stability testing, the design of in vitro drug metabolism assays using various liver fractions (microsomes, S9 fractions), and metabolite ID. Jose’s personal interests include food and wine, traveling, and sailing in the Caribbean.
Zachary Sticher
Associate Development Scientist
Education
Zachary Sticher graduated from Wabash College with a bachelor’s degree in Chemistry and a minor in Economics.
Brief Background
Zachary began his career in a clinical toxicology lab where he developed bioanalytical sample preparation procedures and LC-MS/MS methods for drugs of abuse compliance. He joined EIDD in 2016 and has led the pharmacokinetics group since 2017. He managed the pharmacokinetics group during the pre-clinical development of EIDD-2801 (molnupiravir) and was responsible for writing the pharmacokinetics summary for the IND application for EIDD-2801. He has authored and co-authored eight peer-reviewed publications. Zachary enjoys spending time outdoors playing tennis, golf, and backpacking in National Parks.
Meghan Andrews
Lead Research Specialist
Education
Meghan earned her B.S. degree in Forensic Science and Chemistry with a minor in mathematics from Virginia Commonwealth University.
Brief Background
Meghan Andrews graduated from Virginia Commonwealth University in 2020; her time at school was filled with volunteer work and holding various positions within student organizations she was a part of. She previously worked at Bureau Veritas performing oil and diesel fuel analysis for particulate contamination, grease efficiency, and additive depletion in both fuels and oils. In her free time, she enjoys reading and spending time with her family.
Rebecca Krueger
Lead Research Specialist
Education
Rebecca earned her B.S. degree in biochemistry with minors in psychology and sociology from Louisiana State University.
Brief Background
Rebecca began her career as a laboratory technician in the high-throughput quality control lab at Integrated DNA Technologies (Research Triangle Park), where she determined the identity and purity of oligonucleotides produced on-site using ESI-MS, MCCE, and analytical RP-HPLC. She joined the Emory Institute for Drug Development in 2022 as part of the pharmacokinetics group. Rebecca enjoys reading, spending time with friends and family, and traveling.
McKenzie Smith
Post Doctoral Fellow